ACURA PHARMACEUTICALS, INC

616 N. North Court, Suite 120

Form 8-K

August 01, 2013									
UNITED STATES									
SECURITIES AND EXCHANGE COMMISSION									
WASHINGTON, D. C. 20549									
·									
FORM 8-K									
CURRENT REPORT									
Pursuant to Section 13 or 15(d) of the									
Securities Exchange Act Of 1934									
August 1, 2013									
Date of Report (Date of earliest event reported)									
ACURA PHARMACEUTICALS, INC.									
(Exact Name of Registrant as Specified in Charter)									
State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification Number)									

Palatine, Illinois 60067

1	Address	αf	nrinc	inal	executive	offices)	(7in	Code)
1	Address	OΙ	DITHIC	ibai	executive	offices	(ZID	Code

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-J(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-L(c))

Item 2.02 Results of Operations and Financial Condition

On August 1, 2013 we issued a press release disclosing the financial results for our second quarter ended June 30, 2013. A copy of our press release is being furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

Exhibit Number Description

99.1 Press Release dated August 1, 2013 announcing financial results for the second quarter ended June 30, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By:/s/ Peter A. Clemens
Peter A. Clemens
Senior Vice President & Chief Financial Officer

Palatine, Illinois

Date: August 1, 2013

Exhibit Index

Exhibit Number Description

99.1 Press Release dated August 1, 2013 announcing financial results for the second quarter ended June 30, 2013